C. difficile

Investigators from the University of Houston find that 45% of the positive samples were from the soles of shoes.

Trials show a consistent efficacy profile and a consistent safety profile for RBX2660 in reducing the recurrence of C. difficile infection.

Although there are several conditions known to be risk factors for clostridium difficile, data on the link between malignancy and clostridium difficile are limited.

Individuals in a study who received the food with BB-12 probiotic retained beneficial metabolites produced by the microbiota.

Ten quiz questions to assess your knowledge on common symptoms and treatments for Clostridioides difficile.

From an economic perspective, C. difficile has a staggering financial impact on the US health care system, as well on the patients infected.

A study found individuals receiving probiotics had a decrease in C. difficile diagnosed in stool samples than those who did not receive probiotics.

The treatment was also well-tolerated, with a similar safety profile to placebo, according to the investigators.

Hospitalizations related to C. diff infections can cost more than twice as much as the average hospitalization and can extend patients’ stays by an average of 3.6 days.

Ridinilazole is not currently approved for use by any regulatory authority.

C difficile colonization rates among children were greatest at 6 to 12 months of age but decreased among children older than 5 years of age.

Bezlotoxumab is administered to prevent Clostridium difficile infection from recurring in patients who are receiving treatment for the infection and are at risk for recurrence.

Study findings could offer a new approach to the toxin-based approach of other C. difficile vaccines in development.

This action follows a recently completed phase 2a clinical trial, which demonstrated that 100% of the 10 enrolled patients met the study's primary and secondary efficacy endpoints of clinical cure at end of treatment as well as sustained clinical cure with no recurrence of CDI when examined on a 28-day follow-up visit.

Recurrent C. diff infections were observed in 16% of patients who received bezlotoxumab, compared with 29% of patients who received standard of care alone.

Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.

Panelists also recommended the use of bezlotoxumab as a co-intervention with standard of care antibiotics in patients with a recurrent C. diff infection within the past 6 months.

Pharmacists should educate themselves about the options available to help patients manage this bacterium that causes severe diarrhea and colitis.

Researchers observed the structure of a lethal toxin produced by certain strains of Clostridium difficile bacteria.

Adult patients with Clostrioides difficile infection who received hematopoietic stem cell transplant also benefitted from frontline medications fidaxomicin or oral vancomycin.

The investigational therapy RBX2660 has demonstrated positive trends in efficacy and safety for reducing recurrent Clostridioides difficile (C. difficile) infection over 6 months, in a recent study.

Approximately 450,000 cases of Clostridioides difficile infection occur each year in the United States and approximately 25% of patients treated for an initial episode will experience recurrence.

Further, while there is ambiguity surrounding the treatment of IBD flare in patients with CDI, case reports suggest corticosteroid initiation after appropriate antibiotic therapy may be effective.

The antibiotic fights both resistant enterococcus, streptococcus, and staphylococcus bacteria via a unique mechanism of action, which causes resistance to develop at a very slow pace.

Fecal microbiota transplants are effective in at least 80% of C. diff cases, although until now, researchers did not know why.